Evidence mapPaperPMID 32766006Full record

ReviewCureus2020

Mechanisms of Beta-Blocker Induced Psoriasis, and Psoriasis De Novo at the Cellular Level.

Vanessa M Awad, Sirisha Sakhamuru, Srikala Kambampati, Shehnaz Wasim, Bilal Haider Malik

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Observational
  8. Article
  9. Article
  10. The Role of Helper T Cells in Psoriasis.Frontiers in immunology · 2021
    Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Vanessa M AwadInternal Medicine/Family Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Sirisha SakhamuruInternal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield , USA.
Srikala KambampatiInternal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Shehnaz WasimInternal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Bilal Haider MalikInternal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
California Institute of Behavioral Neurosciences and Psychology (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Beta-blockers are a commonly prescribed medication, but the increase in use goes hand in hand with increasing side effects; one of particular interest lately has been its dermatological reactions. Although rare, beta-blockers can exacerbate pre-existing psoriasis and also cause de novo psoriasis in patients naïve to the disease. The mechanism by which this occurs is still unclear, although numerous articles have been published throughout the years as to how this unusual effect takes place. The most common mechanism suggests that beta-blockers cause intracellular changes in calcium, affecting both keratinocyte proliferation and granulocyte function via decreased cyclic adenosine monophosphate (cAMP) levels. Several inflammatory mediators are known to play a role, as well as reduced expression and desensitization of the beta-adrenergic receptor itself. We discuss these posed pathways in-depth and how each contributes to the worsening or formation of new psoriasis. With this knowledge, future physicians may be more mindful of this side effect should it occur, and why they occur, to better manage our patients on this widely used medication.

Indexed as

beta-blockadebeta-blocker induced psoriasisbeta-blocker side effectscalcium effects on keratinocytesdrug-induced psoriasismechanism of beta-blocker psoriasispsoriasis/drug therapy

Identifiers

PMID32766006
PMCPMC7398737
OpenAlexW3039695269

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.